Core Viewpoint - The 17th Ditan Traditional Chinese Medicine Health Culture Festival was successfully held in Beijing, showcasing the integration of traditional culture and health through various TCM products and practices [1]. Company Overview - Tongrentang Technology Development Co., Ltd. showcased a wide range of health products, emphasizing its strength in the health industry and innovative capabilities [3][5]. - The company has developed a product matrix in the health sector, including six major categories: health foods, health drinks, deer products, cosmetics, fragrance products, and disinfection products [3]. Product Highlights - The festival featured dozens of representative products from the "big health" matrix, demonstrating the company's rich heritage in TCM culture and product development [5]. - The traditional production technique of Ejiao cake was demonstrated live, highlighting the craftsmanship and time-intensive process involved [7]. - The company has developed nearly 200 fragrance products based on classic TCM formulas, integrating traditional medicine with modern fragrance techniques [9][11]. - The cosmetics division focuses on the research and application of traditional plants, with products like ginseng vitamin E lotion gaining popularity among consumers [13]. Cultural Impact - The festival allowed the public to deeply experience the charm of TCM culture and health services, promoting the benefits of TCM to a wider audience [15].

Policy Developments - The National Medical Products Administration (NMPA) has announced the implementation of the "Quality Management Standards for Online Sales of Medical Devices," effective from October 1, 2025. Regulatory authorities are required to guide online sellers and e-commerce platforms in conducting internal training and assessments related to quality management systems, product information display, and risk monitoring [2]. Drug and Device Approvals - BeiGene announced positive results from the Phase 2 clinical trial (DeLLphi-307) of tarlatamab for treating extensive-stage small cell lung cancer (ES-SCLC) patients in China, with detailed data to be presented at an upcoming medical conference [4]. Capital Market Activities - Shanghai BoYin Biotechnology Co., Ltd. has completed a multi-million angel round financing, led by Zhangjiang Life and Health Industry Incubation Angel Fund, with funds aimed at advancing the company's product pipeline and early clinical validation of its first product [7]. Industry Developments - Yuheng Pharmaceutical has signed a co-promotion agreement with Xinghe Pharmaceutical for Pemafibrate, a novel selective PPARα modulator, which will take effect on June 1, 2025. This agreement is expected to enhance Yuheng's product pipeline and potential profit growth, although it will face competition from established products [9]. Shareholder Activities - Chengdu XianDao announced that shareholder Anji Dongfang Jiayu Enterprise Management Partnership reduced its stake by 1 million shares, decreasing its ownership from 6.2% to 5.95% [12]. - BioVeda China RMB Investment Limited plans to reduce its stake in AoJing Medical by up to 135,550 shares, having already reduced its holdings by 34,510 shares, representing 0.25% of the total shares [13].

Group 1: Product License Announcement - Beijing Tongrentang Co., Ltd. has received a Class III product license from Health Canada for its product Suhexiang Wan, allowing for potential sales in Canada [1][2] - The total research and development investment for the product by Tongrentang Pharmaceutical Factory amounts to approximately 3.05 million yuan (about 0.46 million USD) as of the announcement date [1] Group 2: Impact on Company Operations - The approval of the product license is a significant step towards market entry, but further administrative approvals, including Canadian production quality system certification, are required, which may introduce uncertainties [2] - The recent approval is not expected to have a major impact on the company's short-term operating performance [2] Group 3: Annual Shareholders Meeting Notification - The 2024 Annual Shareholders Meeting is scheduled for June 16, 2025, and will utilize a combination of on-site and online voting methods [5][6] - The meeting will take place at the company's headquarters in Beijing, with specific voting times outlined for both on-site and online participants [6][10] Group 4: Voting Procedures and Participation - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with detailed instructions provided for participation [10][11] - The company aims to facilitate participation from minority investors by sending reminders and information about the meeting and voting procedures [10]

Core Insights - A new trend of "punk health" is emerging among young consumers, transforming traditional Chinese herbal medicine concepts into modern beverage choices [2][3] - The market for Chinese health drinks has grown significantly, from 0.1 billion yuan in 2018 to 4.5 billion yuan in 2023, with projections to exceed 10 billion yuan by 2028 [2][3] - The rise of health drinks is reshaping the competitive landscape of the beverage market, with products like melatonin sparkling water and ginseng electrolyte water gaining popularity [2][3] Market Dynamics - The average price of Chinese health drinks is around 5-6 yuan per bottle, offering a cost-effective health option compared to 2 yuan for bottled water [3] - Health drinks are becoming a form of emotional consumption for young people, with significant engagement on social media platforms, such as 220 million views for "Chinese health" tags on Xiaohongshu [3][4] - The demand for functional beverages is increasing, with a notable shift from traditional sugary drinks to healthier options like sugar-free tea and herbal drinks [4][10] Competitive Landscape - The market for health drinks is becoming increasingly competitive, with brands like Yuanqi Forest leading the charge by launching health-focused products that quickly sell out [6][7] - New entrants and established brands are entering the health drink space, with Yuanqi Forest's health water series achieving over 1 billion yuan in sales in 2024 [7][8] - Brands are focusing on unique packaging, ingredients, and flavors to differentiate themselves in a crowded market [8][9] Consumer Behavior - Young consumers are increasingly health-conscious, seeking beverages that offer nutritional benefits, improved immunity, and better sleep [10][12] - There is a growing concern over product homogeneity and price wars, as many brands offer similar health drinks with overlapping ingredients [11][12] - Consumer loyalty is low, with buyers often comparing prices and ingredients before making a purchase decision [12][14] Future Trends - The health drink market is expected to continue evolving, with brands needing to find differentiation to capture consumer interest [14] - The industry is moving towards a focus on natural ingredients and functional benefits, as consumers demand more from their beverage choices [8][10]

北京同仁堂股份有限公司（以下简称公司）分支机构北京同仁堂股份有限公 司同仁堂制药厂（以下简称同仁堂制药厂）收到加拿大卫生部核准签发的《产品 许可证（三类）》，同仁堂制药厂产品苏合香丸获得加拿大产品注册。公司现将有 关情况公告如下： 证券代码：600085 证券简称：同仁堂 公告编号：2025-011 | 产品 | 品种批准文 | 剂型 | 适应症 | 持证商 | 持证商地址 | | --- | --- | --- | --- | --- | --- | | 名称 | 号（NPN） | | | 名称 | | | | | | 1.本品为传统中药成 | 北京同 | 北京市大兴区 中关村科技园 | | | | | 分的组合。 | 仁堂股 | | | 苏合 | | | 2.传统中药用于芳香 | 份有限 | | | | 80138750 | 丸剂 | | | 区大兴生物医 | | 香丸 | | | 开窍，行气止痛。 | 公司同 | | | | | | | | 药产业基地天 | | | | | 3.传统中药用于中暑、 | 仁堂制 | 贵大街 33 号 | | | | | 心胃气痛。 | 药厂 | | 北京同仁堂股份有限公司 ...

证券代码：600085 证券简称：同仁堂 公告编号：2025-012 北京同仁堂股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次：2024年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 16 日 9 点 30 分 召开地点：北京市大兴区中关村科技园区大兴生物医药产业基地天贵大街 33 号北京同仁堂股份有限公司会议室 (五) 网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 16 日 至2025 年 6 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:0 ...

Core Viewpoint - Tong Ren Tang's product Su He Xiang Wan has received a product license from Health Canada, marking a significant step towards potential sales in Canada, although further administrative approvals are required [1] Group 1 - The company announced that its subsidiary, Tong Ren Tang Pharmaceutical Factory, has been granted a Class III product license for Su He Xiang Wan by Health Canada [1] - The product must still undergo additional administrative approvals, including Canadian production quality system certification, before it can be sold in Canada [1] - The recent approval is not expected to have a significant impact on the company's short-term operating performance [1]

Core Insights - The health nutrition industry is undergoing structural transformation due to heightened health awareness, stricter regulations, and a return to rational consumption, leading brands to adjust pricing, optimize inventory, and focus on channel and profit model reconstruction [1][2]. Industry Overview - The health nutrition industry is entering a high-quality development phase in 2024, driven by policy, economic, capital, and technological synergies [10]. - Regulatory bodies are enhancing the registration and filing standards for health nutrition products, increasing oversight across production and sales [11]. Product Category Situation - The industry is focusing on four core consumer groups: middle-aged working individuals, high-net-worth individuals, rehabilitation needs, and the elderly [52]. - Key product categories gaining attention include immune enhancement, joint and bone care, and probiotics, while categories like anti-aging are experiencing a decline [54][56]. Financing Trends - In 2024, the number of financing events in the health nutrition industry decreased, but the total financing amount increased, with upstream companies, particularly probiotic suppliers, being favored by investors [16][17]. - The financing amount rose by 3.21 billion yuan despite a reduction in the number of financing events [18]. Sales Channel Dynamics - Private domain e-commerce has surpassed traditional pharmaceutical chains for the first time, with platforms like Douyin Global Purchase emerging as significant players in the cross-border B2C market [2][30]. - Retailers are increasingly adopting a "direct procurement" model, with over 25% of retailers sourcing products directly from manufacturers [31]. Strategic Adjustments - In response to market pressures, 60% of small and medium-sized enterprises are reducing R&D investments and shifting towards OEM models to maintain cash flow [27]. - Major brands are enhancing their channel, product, and marketing strategies, focusing on dual strategies of high-end and affordable products [26]. Consumer Preferences - The average transaction price for core products in the health nutrition sector has significantly decreased, with 31% of companies reporting prices in the 50-100 yuan range in 2024, up 17.22% from 2023 [14][15]. - The demand for personalized and functional health products is rising, particularly among younger consumers and new parents [81][84]. Future Outlook - By 2025, nearly 42% of companies anticipate that tightening policies and consumer downgrade will hinder rapid growth in the industry [35]. - Brands are expected to shift their focus towards value-driven strategies, including price adjustments and new channel explorations, to sustain growth [37][41].

证券研究报告 | 金融工程 2025 年 05 月 24 日 刚需+出海+历史低位，多重因素凸显制药价值 ——华宝中证制药 ETF 投资价值分析 随着保健意识的提升及国内人口老龄化趋势的发展，药品作为人们生活中的刚 性需求，其市场需求量日益增长。从供给端来看，原研药专利集中到期，创新 药频获出海订单，中药受政策大力扶持，各细分领域药企均迎来发展机遇。时 逢相关标的位于历史的价格低位，药品制造业显示出一定的投资机会。华宝中 证制药 ETF（认购代码：562053.OF）通过紧密跟踪中证制药指数，一键式配 置制药行业优质上市企业，值得投资者关注。 任瞳 S1090519080004 rentong@cmschina.com.cn ❑ 风险提示：本报告仅作为投资参考，基金产品过往业绩并不预示其未来表 现，亦不构成投资收益的保证或投资建议，新发基金无历史业绩可参考。 敬请阅读末页的重要说明 专题报告 ❑ 在新兴市场经济快速发展和各国医疗保障制度的逐渐完整之下，全球医药 市场规模仍旧维持着稳定增长态势。而据统计，我国的人均药品用量仍远 低于世界发达国家水平，国内药品用量的需求增长仍然具有较大的空间。 ❑ 在供给端，各细 ...

Core Viewpoint - Tongrentang reported a slight increase in revenue and net profit for Q1 2025, but concerns remain regarding the sustainability of this growth due to high inventory levels and declining sales of core products [2][3][4]. Financial Performance - In Q1 2025, Tongrentang achieved revenue of 5.276 billion yuan, a marginal increase of 0.16% compared to 5.267 billion yuan in Q1 2024 [3]. - The net profit attributable to shareholders was 582 million yuan, reflecting a year-on-year growth of 1.10% [3]. Inventory and Sales Concerns - The company faces significant inventory issues, with inventory turnover days increasing from 294.21 days in 2022 to 346.65 days in 2024 [6]. - Sales volumes for key product categories, such as cardiovascular and tonic products, decreased by 2.27% and 2.67% respectively [5][6]. Prepayment and Demand Weakness - Tongrentang's contract liabilities, particularly prepayments, halved year-on-year to 311 million yuan, indicating weak sales performance [8][9]. Cost Pressures - The company is experiencing substantial cost increases due to raw material price hikes, with natural cow bile prices rising nearly threefold from 430 yuan per gram in 2020 to 1700 yuan per gram in 2025 [10]. - The total inventory value increased from 9.316 billion yuan at the beginning of 2024 to 10.708 billion yuan by the end of the year, a growth of approximately 14.94% [10]. Profitability Challenges - The gross profit margin has declined by 3.34 percentage points in 2024, with retail and wholesale margins decreasing by 2.55 and 6.60 percentage points respectively [15]. - Despite price increases for products, the company’s ability to maintain profitability is under scrutiny as cost growth outpaces revenue growth [14][16].